The increase in heart rate in the setting of chronic coronary artery disease is associated with poor prognosis, especially increased risk of acute myocardial infarction. Reducing heart rate with ibravadina inhibitor may confer symptomatic benefit of angina and reduce coronary events in patients with chronic coronary disease and a resting heart rate ≥ 70 bpm. After a mean follow up of 27.8 months, no significant difference was observed for the occurrence of events between ibravadina group and the placebo group.
Kim Fox
2014-08-31
Original title: Ivabradine in patients with stable coronary artery disease without clinical heart failure: The results of SIGNIFY.
